Core Viewpoint - Weigao Co., Ltd. reported a revenue of 1.539 billion RMB for the fiscal year 2025, reflecting a year-on-year growth of 5.95%, and a net profit attributable to shareholders of 267 million RMB, which is a 19.17% increase compared to the previous year [1][1][1] Financial Performance - The company achieved an operating income of 1.539 billion RMB, marking a 5.95% increase year-on-year [1] - The net profit attributable to the parent company was 267 million RMB, representing a year-on-year growth of 19.17% [1] - Basic earnings per share stood at 0.67 RMB [1] Market and Sales Strategy - The overall execution of orthopedic bulk procurement remained stable, with leading domestic brands increasing their market share [1] - The company actively adjusted its sales model and organizational structure, establishing a profit center system centered around professional departments to enhance marketing efficiency [1] - Product lines were further segmented, allowing for improved management and specialization within the sales team, leading to more precise clinical services and academic leadership in the market [1] - Focus on key surgical procedures through multi-product line collaborative sales resulted in significant growth in core hospital business, alongside increased efforts in developing lower-tier markets and promoting innovative products [1]